share_log

Don't Ignore The Insider Selling In Pacific Biosciences of California

Don't Ignore The Insider Selling In Pacific Biosciences of California

不要忽視加州太平洋生物科學的內幕銷售
Simply Wall St ·  01/15 14:15

Anyone interested in Pacific Biosciences of California, Inc. (NASDAQ:PACB) should probably be aware that the Chief Operating Officer, Mark Van Oene, recently divested US$241k worth of shares in the company, at an average price of US$7.77 each. The eyebrow raising move amounted to a reduction of 12% in their holding.

任何對加州太平洋生物科學公司(納斯達克股票代碼:PACB)感興趣的人都應該知道,首席運營官馬克·範·奧恩最近以每股7.77美元的平均價格剝離了該公司價值24.1萬美元的股份。此次舉措使他們的持股量減少了12%。

See our latest analysis for Pacific Biosciences of California

查看我們對加州太平洋生物科學公司的最新分析

Pacific Biosciences of California Insider Transactions Over The Last Year

加州太平洋生物科學公司去年內幕交易

In the last twelve months, the biggest single sale by an insider was when the President, Christian O. Henry, sold US$980k worth of shares at a price of US$10.12 per share. We generally don't like to see insider selling, but the lower the sale price, the more it concerns us. The good news is that this large sale was at well above current price of US$6.71. So it is hard to draw any strong conclusion from it.

在過去的十二個月中,內部人士最大的一次出售是總裁克里斯蒂安·奧·亨利以每股10.12美元的價格出售了價值9.8萬美元的股票。我們通常不喜歡看到內幕銷售,但是銷售價格越低,我們就越擔心。好消息是,此次大宗銷售遠高於當前6.71美元的價格。因此,很難從中得出任何強有力的結論。

Insiders in Pacific Biosciences of California didn't buy any shares in the last year. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

加州太平洋生物科學公司的內部人士去年沒有購買任何股票。你可以在下面看到過去 12 個月的內幕交易(公司和個人)的直觀描述。如果你想確切地知道誰賣了、賣了多少以及何時出售,只需點擊下圖!

insider-trading-volume
NasdaqGS:PACB Insider Trading Volume January 15th 2024
納斯達克股票代碼:PACB 內幕交易量 2024 年 1 月 15 日

If you are like me, then you will not want to miss this free list of growing companies that insiders are buying.

如果你像我一樣,那麼你不會想錯過這份業內人士正在收購的成長型公司的免費名單。

Insider Ownership Of Pacific Biosciences of California

加州太平洋生物科學公司的內部所有權

Many investors like to check how much of a company is owned by insiders. A high insider ownership often makes company leadership more mindful of shareholder interests. From our data, it seems that Pacific Biosciences of California insiders own 0.3% of the company, worth about US$5.5m. We do generally prefer see higher levels of insider ownership.

許多投資者喜歡查看公司內部人士擁有多少股份。較高的內部所有權通常會使公司領導層更加關注股東的利益。從我們的數據來看,加州太平洋生物科學公司的內部人士似乎擁有該公司0.3%的股份,價值約550萬美元。我們通常更願意看到更高的內部所有權水平。

So What Does This Data Suggest About Pacific Biosciences of California Insiders?

那麼,這些數據對加州內部人士的太平洋生物科學有何啓示呢?

An insider sold Pacific Biosciences of California shares recently, but they didn't buy any. And there weren't any purchases to give us comfort, over the last year. When you consider that most companies have higher levels of insider ownership, we're a little wary. So we'd only buy after very careful consideration. While we like knowing what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. Every company has risks, and we've spotted 4 warning signs for Pacific Biosciences of California you should know about.

一位內部人士最近出售了加利福尼亞太平洋生物科學公司的股票,但他們沒有購買任何股票。在過去的一年裏,沒有任何能讓我們感到安慰的購買。當你考慮到大多數公司的內部所有權水平更高時,我們有點警惕。因此,我們只有在經過仔細考慮後才會購買。雖然我們喜歡了解內部人士的所有權和交易情況,但在做出任何投資決策之前,我們一定要考慮股票面臨的風險。每家公司都有風險,我們發現了你應該知道的加利福尼亞太平洋生物科學公司的4個警告信號。

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.

當然,通過尋找其他地方,你可能會找到一筆不錯的投資。因此,來看看這份有趣的公司的免費清單吧。

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

就本文而言,內部人士是那些向相關監管機構報告交易的個人。我們目前僅對公開市場交易和直接權益的私人處置進行覈算,但不包括衍生品交易或間接權益。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St 的這篇文章本質上是籠統的。我們僅使用公正的方法提供基於歷史數據和分析師預測的評論,我們的文章並非旨在提供財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不會考慮最新的價格敏感型公司公告或定性材料。華爾街只是沒有持有上述任何股票的頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論